Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma globulins are a major class of serum proteins, predominantly consisting of immunoglobulins (antibodies) such as IgG, IgA, and IgM, which are critical components of the adaptive immune system (StatPearls, 2023). Produced by plasma cells, these proteins recognize and bind to specific antigens on pathogens, facilitating their neutralization or destruction through mechanisms like opsonization and complement activation (Britannica, 2024). In clinical practice, gamma globulin preparations, such as intravenous immunoglobulin (IVIG), are administered as replacement therapy for primary immunodeficiency or as immunomodulators for autoimmune conditions like immune thrombocytopenia (ITP) (Mayo Clinic, 2023). Furthermore, specific immunoglobulins or the pathways regulating their persistence, such as the neonatal Fc receptor (FcRn), have become significant therapeutic targets. Drugs like FcRn inhibitors (e.g., efgartigimod) are designed to lower the levels of pathogenic IgG autoantibodies in diseases such as myasthenia gravis by preventing their recycling and promoting degradation (Nature Reviews Drug Discovery, 2022). Monitoring gamma globulin levels via serum protein electrophoresis or specific assays is essential for diagnosing plasma cell dyscrasias and assessing the efficacy of B-cell depleting or FcRn-targeting therapies (NCBI, 2022).
Neonatal Fc receptor (FcRn) antagonism to increase IgG catabolism (Nature Reviews Drug Discovery, 2022); direct neutralization of circulating IgE to prevent allergic cascades (PubMed, 2023); and passive immunization through exogenous administration (StatPearls, 2023).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin (Ig) (Ig).